FindTrial
Sign In

Multi-Center Clinical Study on the Efficacy and Safety of Almonertinib Combined with Bevacizumab and Pemetrexed in the First-Line Treatment of EGFR-Mutant Lung Adenocarcinoma Patients with Brain Metastases

Multi-Center Clinical Study on the Efficacy and Safety of Almonertinib Combined with Bevacizumab and Pemetrexed in the First-Line Treatment of EGFR-Mutant Lung Adenocarcinoma Patients with Brain Metastases

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035591
Enrollment
Unknown
Registered
2020-08-14
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Adenocarcinoma

Interventions

Treatment Group:Almonertinib Combined with Bevacizumab and Pemetrexed

Sponsors

Shandong Cancer Hospital Affiliated to Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1)Male or female, age at least 18 years. 2) Life expectancy is more than three months. 3) Histology or cytology confirmed stage lung adenocarcinoma. 4) A WHO performance status equal to 0-1. 5) The tumour harbours one of the EGFR mutations (Ex19del, L858R, G719AG719CG719SL861Q). 6) Patients with at least one measurable intracranial lesion and there are asymptomatic.

Exclusion criteria

Exclusion criteria: 1) Mixed NSCLC with squamous cell; 2) If there are small cell carcinoma, neuroendocrine carcinoma and sarcoma components in mixed lung cancer; 3) Had received chemotherapy or EGFR-TKIS before; Who receive adjuvant or neoadjuvant therapy, and the time from the last treatment to recurrence is less than 6 months.

Design outcomes

Primary

MeasureTime frame
progression-free survival;intracranial progression-free survival;—

Secondary

MeasureTime frame
objective response rate;intracranial objective response rate;safety;—

Countries

China

Contacts

Public ContactJie Liu

Shandong Cancer Hospital Affiliated to Shandong University

Lj691012@126.com+86 15553119051

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026